Coldstream Capital Management Inc. Increases Stock Position in Stryker Co. (NYSE:SYK)

Coldstream Capital Management Inc. boosted its position in shares of Stryker Co. (NYSE:SYK) by 3.7% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 7,621 shares of the medical technology company’s stock after acquiring an additional 273 shares during the period. Coldstream Capital Management Inc.’s holdings in Stryker were worth $2,744,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Stryker in the 4th quarter worth $25,000. Rakuten Securities Inc. grew its position in Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after acquiring an additional 68 shares in the last quarter. Centricity Wealth Management LLC purchased a new position in Stryker in the fourth quarter worth about $30,000. BankPlus Trust Department bought a new stake in Stryker during the fourth quarter worth approximately $33,000. Finally, Activest Wealth Management bought a new stake in shares of Stryker in the 4th quarter valued at approximately $36,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is owned by insiders.

Stryker Price Performance

NYSE SYK opened at $365.34 on Friday. The company has a market cap of $139.45 billion, a PE ratio of 47.08, a P/E/G ratio of 2.93 and a beta of 0.93. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The firm’s 50 day moving average price is $367.81 and its 200-day moving average price is $373.30.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the company posted $3.46 earnings per share. Sell-side analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.92%. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. The Goldman Sachs Group set a $422.00 price target on Stryker in a research report on Tuesday, March 4th. Truist Financial lifted their price target on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research note on Thursday, January 30th. Royal Bank of Canada increased their price objective on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. Wells Fargo & Company boosted their target price on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Finally, Stifel Nicolaus boosted their price objective on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $423.53.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.